JP2009529906A - 免疫応答を調節するための組成物および方法 - Google Patents

免疫応答を調節するための組成物および方法 Download PDF

Info

Publication number
JP2009529906A
JP2009529906A JP2009500939A JP2009500939A JP2009529906A JP 2009529906 A JP2009529906 A JP 2009529906A JP 2009500939 A JP2009500939 A JP 2009500939A JP 2009500939 A JP2009500939 A JP 2009500939A JP 2009529906 A JP2009529906 A JP 2009529906A
Authority
JP
Japan
Prior art keywords
fusion protein
polypeptide
receptor
sequence
antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009500939A
Other languages
English (en)
Japanese (ja)
Other versions
JP2009529906A5 (enExample
Inventor
コラコ，カミーロ
Original Assignee
イムノバイオロジー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by イムノバイオロジー リミテッド filed Critical イムノバイオロジー リミテッド
Publication of JP2009529906A publication Critical patent/JP2009529906A/ja
Publication of JP2009529906A5 publication Critical patent/JP2009529906A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/14011—Baculoviridae
    • C12N2710/14111—Nucleopolyhedrovirus, e.g. autographa californica nucleopolyhedrovirus
    • C12N2710/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2009500939A 2006-03-22 2007-03-22 免疫応答を調節するための組成物および方法 Pending JP2009529906A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0605735.0A GB0605735D0 (en) 2006-03-22 2006-03-22 Composition and method for mediating an immune response
PCT/GB2007/050143 WO2007107797A2 (en) 2006-03-22 2007-03-22 Fusion protein comprising an fc receptor binding polypeptide and an antigenic polypeptide for mediating an immune response

Publications (2)

Publication Number Publication Date
JP2009529906A true JP2009529906A (ja) 2009-08-27
JP2009529906A5 JP2009529906A5 (enExample) 2011-08-18

Family

ID=36383953

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009500939A Pending JP2009529906A (ja) 2006-03-22 2007-03-22 免疫応答を調節するための組成物および方法

Country Status (6)

Country Link
US (2) US20090186025A1 (enExample)
EP (1) EP2007807A2 (enExample)
JP (1) JP2009529906A (enExample)
CN (2) CN101448854A (enExample)
GB (1) GB0605735D0 (enExample)
WO (1) WO2007107797A2 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0615266D0 (en) * 2006-08-01 2006-09-06 Immunobiology Ltd Composition and method for mediating an immune response
CA2915168C (en) 2007-01-30 2017-05-23 Epivax, Inc. Regulatory t cell epitopes, compositions and uses thereof
TWI422594B (zh) 2007-02-02 2014-01-11 Baylor Res Inst 經由樹狀細胞去唾液酸糖蛋白受體（ｄｃ-ａｓｇｐｒ）接合抗原呈現細胞之藥劑
TWI423985B (zh) * 2007-02-23 2014-01-21 Baylor Res Inst 利用ｄｅｃｔｉｎ-１活化人類抗原呈現細胞之醫療應用
WO2011044158A1 (en) 2009-10-09 2011-04-14 New York Blood Center, Inc. Immunopotentiator-linked oligomeric influenza immunogenic compositions
AU2013295647B2 (en) * 2012-07-26 2018-02-08 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Multimeric fusion protein vaccine and immunotherapeutic
CN106659774A (zh) 2014-05-16 2017-05-10 贝勒研究院 用于治疗自身免疫和炎性病症的方法和组合物
EP3253797A4 (en) * 2015-02-03 2018-10-03 Jyant Technologies, Inc. Chemokine-immunoglobulin fusion polypeptides, compositions, method of making and use thereof
CN106146670B (zh) * 2015-04-24 2019-01-15 宜明昂科生物医药技术（上海）有限公司 一种新的重组双功能融合蛋白及其制备和应用
CN106366179A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种跨膜硫酸乙酰肝泰蛋白多糖1免疫激动剂多肽及其用途
CN106366180A (zh) * 2016-08-28 2017-02-01 苏州普罗达生物科技有限公司 一种上皮生长因子受体免疫原多肽及其用途
CN106337040A (zh) * 2016-08-28 2017-01-18 苏州普罗达生物科技有限公司 一种内皮细胞受体蛋白酪氨酸激酶a2免疫原多肽及其用途
US20220073630A1 (en) * 2018-12-28 2022-03-10 Hoffmann-La Roche, Inc. A peptide-mhc-i-antibody fusion protein for therapeutic use in a patient with amplified immune response
CN110093360B (zh) * 2019-04-15 2021-06-15 华南农业大学 一种表达Fc片段的狂犬病病毒G蛋白的融合蛋白及其制备方法
CN112870344B (zh) * 2019-11-29 2022-07-19 北京绿竹生物技术股份有限公司 一种重组水痘带状疱疹病毒疫苗
CN110872358B (zh) * 2019-12-04 2021-12-10 天康制药(苏州)有限公司 HA-Fc融合蛋白及其制备方法和疫苗
CA3211083A1 (en) * 2021-03-04 2022-09-09 Kyle BACKMAN Compositions including sbi adjuvants and methods of use thereof
CN116769014A (zh) * 2023-06-07 2023-09-19 河南省农业科学院动物免疫学重点实验室 一种牛IgG Fc受体boFcγRI的线性配体结合表位
CN119841940B (zh) * 2025-03-19 2025-06-20 中国人民解放军军事科学院军事医学研究院 一种抗基孔肯雅病毒e蛋白的纳米抗体n033及其应用

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500670A (ja) * 1994-05-13 1998-01-20 エクラゲン リミテッド ペプチド送達の改良またはペプチド送達との関連
WO2000001732A2 (en) * 1998-07-06 2000-01-13 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2004534511A (ja) * 2000-11-27 2004-11-18 プラエシス ファーマシューティカルズ インク． アミロイド形成性疾患を治療するための治療薬及びその使用法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5969109A (en) * 1990-02-28 1999-10-19 Bona; Constantin Chimeric antibodies comprising antigen binding sites and B and T cell epitopes
US6391589B1 (en) * 1994-08-23 2002-05-21 Human Genome Sciences, Inc. Human chemokine beta-10 mutant polypeptides
US7183387B1 (en) * 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US7067110B1 (en) * 1999-07-21 2006-06-27 Emd Lexigen Research Center Corp. Fc fusion proteins for enhancing the immunogenicity of protein and peptide antigens
GB0102145D0 (en) * 2001-01-26 2001-03-14 Scancell Ltd Substances
US20040002587A1 (en) * 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8025873B2 (en) * 2002-06-20 2011-09-27 Paladin Labs, Inc. Chimeric antigens for eliciting an immune response
US8007805B2 (en) * 2003-08-08 2011-08-30 Paladin Labs, Inc. Chimeric antigens for breaking host tolerance to foreign antigens

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10500670A (ja) * 1994-05-13 1998-01-20 エクラゲン リミテッド ペプチド送達の改良またはペプチド送達との関連
WO2000001732A2 (en) * 1998-07-06 2000-01-13 The University Of Tennessee Research Corporation Compounds, compositions and methods for the endocytic presentation of immunosuppressive factors
JP2004534511A (ja) * 2000-11-27 2004-11-18 プラエシス ファーマシューティカルズ インク． アミロイド形成性疾患を治療するための治療薬及びその使用法

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6012027118; 大沢利昭ら: 免疫学辞典 第２版, 2001, 第１０３-１０４頁 *
JPN6012027123; 堀内浩幸ら: Ｆｏｏｄｓ　Ｆｏｏｄ　Ｉｎｇｒｅｄｉｅｎｔｓ　Ｊ．　Ｊｐｎ． Ｖｏｌ．２１１，　Ｎｏ．１１, 2006, ｐｐ．９４８-９５５ *
JPN6012027125; ＰＡＲＫ，　Ｃ．-Ｇ．　ｅｔ　ａｌ．: Ｐｈａｒｍ．　Ｒｅｓ． Ｖｏｌ．２０，　Ｎｏ．８, 2003, ｐｐ．１２３９-１２４８ *
JPN6012027128; ＪＯＨＮＳＯＮ，　Ｇ．　ａｎｄ　ＷＵ，　Ｔ．Ｔ．: Ｎｕｃｌｅｉｃ　Ａｃｉｄｓ　Ｒｅｓ． Ｖｏｌ．２８，　Ｎｏ．１, 2000, ｐｐ．２１４-２１８ *

Also Published As

Publication number Publication date
CN101448854A (zh) 2009-06-03
WO2007107797A3 (en) 2007-11-08
GB0605735D0 (en) 2006-05-03
WO2007107797A2 (en) 2007-09-27
US20090186025A1 (en) 2009-07-23
EP2007807A2 (en) 2008-12-31
US20120225067A1 (en) 2012-09-06
CN103396495A (zh) 2013-11-20

Similar Documents

Publication Publication Date Title
JP2009529906A (ja) 免疫応答を調節するための組成物および方法
US12005115B2 (en) Epstein-barr virus vaccines
KR101983989B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
Jegaskanda et al. Influenza-specific antibody-dependent cellular cytotoxicity: toward a universal influenza vaccine
JP6735269B2 (ja) インフルエンザウイルスワクチンおよびその使用
JP2016202185A (ja) ホモ二量体タンパク質コンストラクト
Grødeland et al. The specificity of targeted vaccines for APC surface molecules influences the immune response phenotype
KR102777000B1 (ko) 인플루엔자 바이러스 백신 및 이의 용도
US12297233B2 (en) FcRn-targeted mucosal vaccination against influenza infections
US20230015320A1 (en) Method for preventing or treating influenza virus infection using pharmaceutical composition comprising immunoglobulin fc-fused interleukin-7 fusion protein
CN104136039A (zh) 靶向交叉呈递的树突状细胞的疫苗体
Ghaemi et al. Recombinant COVID-19 vaccine based on recombinant RBD/Nucleoprotein and saponin adjuvant induces long-lasting neutralizing antibodies and cellular immunity
JP2018052953A (ja) インフルエンザウイルスワクチンおよびその使用
AU2008350273B2 (en) HIV-1 envelope glycoprotein oligomer and methods of use
WO2008015480A2 (en) Composition and method for modulating an immune response
JP2024532763A (ja) 切断型インフルエンザノイラミニダーゼおよびこれを使用する方法
US20240398928A1 (en) Immunogenic compositions and their use
CN117836001A (zh) 免疫原性组合物及其用途
JP2020162607A (ja) インフルエンザウイルスワクチンおよびその使用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20100318

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20100318

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20110630

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20120605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20121106